- Molecular NameVerapamil
- SynonymVerapamil [Usan:Ban:Inn]; Verapamil HCl; Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]
- Weight444.747
- Drugbank_IDDB00661
- ACS_NO52-53-9
- Show 2D model
- LogP (experiment)3.8
- LogP (predicted, AB/LogP v2.0)10.09
- pka8.9
- LogD (pH=7, predicted)10.09
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-10.7
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors0
- No.of Rotatable Bonds15
- TPSA0.0
- StatusFDA approved
- AdministrationOral, Intravenous
- PharmacologyAn L-type calcium channel blocker of the phenylalkylamine class. It has been used in the treatment of hypertension, angina pectoris, cardiac arrhythmia, and most recently, cluster headaches.
- Absorption_value95.0
- Absorption (description)Given orally, 90–100% of Verapamil is absorbed,
- Caco_2-4.58
- Bioavailability22.0
- Protein binding90.0
- Volume of distribution (VD)5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmVerapamil is a substrate for CYP3A4, CYP2C9, and other CYPs. It is metabolized in the liver to at least 12 inactive metabolites (though one metabolite, norverapamil, retains 20% of the vasodilating activity of the parent drug).
- Half lifeVerapamil about 4 h, increased during long term oral dosing and in subjects with liver disease; norverapamil about 5~13 h.
- ExcretionAs its metabolites, 70% is excreted in the urine and 16% in feces; 3–4% is excreted unchanged in urine.
- Urinary Excretion<3
- Clerance15 ml/min/kg
- ToxicityLD50=8 mg/kg (i.v. in mice)
- LD50 (rat)N/A
- LD50 (mouse)N/A